STAAR Surgical Company (NASDAQ:STAA) Shares Bought by Defender Capital LLC.

Defender Capital LLC. lifted its position in STAAR Surgical Company (NASDAQ:STAA - Free Report) by 2.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 720,532 shares of the medical instruments supplier's stock after buying an additional 18,965 shares during the quarter. STAAR Surgical comprises approximately 5.0% of Defender Capital LLC.'s holdings, making the stock its 9th biggest position. Defender Capital LLC. owned approximately 1.46% of STAAR Surgical worth $12,653,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in STAA. Raymond James Financial Inc. acquired a new stake in STAAR Surgical in the fourth quarter valued at $923,000. Hsbc Holdings PLC raised its holdings in shares of STAAR Surgical by 21.3% in the 4th quarter. Hsbc Holdings PLC now owns 21,160 shares of the medical instruments supplier's stock valued at $513,000 after purchasing an additional 3,714 shares during the period. Integral Health Asset Management LLC lifted its stake in STAAR Surgical by 100.0% in the 4th quarter. Integral Health Asset Management LLC now owns 100,000 shares of the medical instruments supplier's stock valued at $2,429,000 after purchasing an additional 50,000 shares during the last quarter. Amundi lifted its stake in STAAR Surgical by 174.7% in the 4th quarter. Amundi now owns 23,785 shares of the medical instruments supplier's stock valued at $550,000 after purchasing an additional 15,128 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in STAAR Surgical by 4.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 444,290 shares of the medical instruments supplier's stock worth $10,792,000 after purchasing an additional 18,168 shares during the period. 96.70% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have issued reports on the company. Needham & Company LLC restated a "hold" rating on shares of STAAR Surgical in a research note on Wednesday, May 21st. Stephens restated an "equal weight" rating and issued a $17.00 price target on shares of STAAR Surgical in a research note on Tuesday, March 18th. Canaccord Genuity Group reaffirmed a "hold" rating and set a $20.00 price objective on shares of STAAR Surgical in a research report on Tuesday, May 27th. Wells Fargo & Company assumed coverage on shares of STAAR Surgical in a report on Monday, April 21st. They issued an "equal weight" rating and a $17.00 price objective on the stock. Finally, Piper Sandler upgraded shares of STAAR Surgical to a "hold" rating in a research note on Wednesday, June 18th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $24.63.

STAAR Surgical Trading Up 1.7%

NASDAQ STAA traded up $0.29 during trading on Friday, reaching $17.85. The company's stock had a trading volume of 259,813 shares, compared to its average volume of 852,084. The firm has a 50 day moving average price of $17.94 and a 200 day moving average price of $19.23. The firm has a market capitalization of $884.11 million, a price-to-earnings ratio of -12.40 and a beta of 0.58. STAAR Surgical Company has a 12 month low of $13.50 and a 12 month high of $49.86.

STAAR Surgical declared that its board has initiated a share buyback program on Friday, May 16th that authorizes the company to buyback $30.00 million in shares. This buyback authorization authorizes the medical instruments supplier to repurchase up to 3.2% of its stock through open market purchases. Stock buyback programs are often an indication that the company's board of directors believes its shares are undervalued.

Insider Buying and Selling

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. bought 138,054 shares of STAAR Surgical stock in a transaction on Monday, April 7th. The shares were purchased at an average price of $15.61 per share, with a total value of $2,155,022.94. Following the acquisition, the insider owned 13,332,264 shares in the company, valued at $208,116,641.04. This trade represents a 1.05% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 1.00% of the stock is currently owned by corporate insiders.

STAAR Surgical Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.